Qing Zhang

Ms. Qing Zhang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
QZQing Zhang
Qing Zhang
HWHao Wei
Hao Wei
ALAnnie Lee
Annie Lee
MFMelanie Felmlee
Melanie Felmlee
Γ-hydroxybutyric acid (GHB) is widely abused due to its sedative/hypnotic and euphoric effects. In recent years, GHB use has witnessed a notable rise within the LGBTQ+ community. GHB is a substrate of monocarboxylate transporters (MCTs) and exhibits nonlinear toxicokinetics, characterized by saturable metabolism, absorption, and renal reabsorption. This study investigates the impact of exogenous testosterone administration on GHB toxicokinetics and toxicodynamics, exploring the potential of MCT1 inhibition as a strategy to counteract toxicity. Ovariectomized (OVX) females and castrated (CST) male Sprague Dawley rats were treated with testosterone or placebo for 21 days. GHB was administered at two doses (1000 mg/kg or 1500 mg/kg i.v.), and the MCT1 inhibitor AR-C 155858 (1 mg/kg i.v.) was administered 5 min after GHB (1500 mg/kg i.v.) administration. Plasma and urine were collected up to 8 h post-dose, and GHB concentrations were quantified via a validated LC/MS/MS assay. Sleep time (sedative/hypnotic effect) was utilized as the toxicodynamic endpoint. Testosterone treatment significantly affected GHB toxicokinetics and toxicodynamics. Testosterone-treated CST rats exhibited significantly lower renal clearance, higher AUC, and increased sedative effect, while testosterone-treated OVX rats demonstrated higher metabolic clearance. AR-C 155858 treatment led to an increase in GHB renal and total clearance together with an improvement in sedative/hypnotic effect. In conclusion, exogenous testosterone treatment induces significant alterations in GHB toxicokinetics and toxicodynamics, and MCT inhibition can serve as a potential therapeutic strategy for GHB overdose in both cisgender and transgender male populations.

14 February 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ALAnnie Lee
Annie Lee
QZQing Zhang
Qing Zhang
HWHao Wei
Hao Wei
MFMelanie Felmlee
Melanie Felmlee
Background: Kidney proton- and sodium-dependent monocarboxylate transporters (MCT/SMCT) are involved in the renal reabsorption of substrates, and thus factors involved in their regulation may have pharmacokinetic implications. Previous studies have demonstrated sex hormone-dependent regulation of MCTs and SMCTs in tissues involved in drug disposition. The present study evaluates the impact of puberty on renal MCT/SMCT expression with ovariectomy and castration conducted before puberty, removing the initial exposure to sex hormones. Methods: Male and female rats were castrated or ovariectomized before puberty (4 weeks of age), and subsequently treated with testosterone, 17β-estradiol, progesterone, or both 17β-estradiol and progesterone for 21 days starting at 10 weeks of age. MCT1, CD147, and SMCT1 membrane-bound kidney expression were quantified by Western blot. Results: SMCT1 and CD147 expression were significantly higher in OVX and CST rats treated with testosterone, and testosterone plasma concentrations showed a significant positive correlation with MCT1, SMCT1, and CD147 expression. CD147 expression was significantly downregulated in OVX rats treated with estrogen, compared to placebo controls, and estrogen plasma concentrations were significantly negatively correlated with CD147 expression. Conclusions: Sex and cross-sex hormone treatment altered MCT1, CD147, and SMCT1 expression when gonadectomy was conducted before puberty. The magnitude and direction of the expression differences differed when compared to animals that underwent gonadectomy after puberty, suggesting that sex hormone exposure during puberty plays a key role in MCT1/SMCT1 renal expression. Further studies are needed to elucidate the underlying mechanisms for the differential regulation of MCTs/SMCTs when gonadectomy occurs before or after puberty.

31 August 2026 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
HWHao Wei
Hao Wei
ALAnnie Lee
Annie Lee
QZQing Zhang
Qing Zhang
MFMelanie Felmlee
Melanie Felmlee
Background/Objectives: Non-medical use of GHB poses a public health risk due to the risk of overdose. GHB exhibits nonlinear toxicokinetics mediated by monocarboxylate transporters (MCTs), and previous studies have demonstrated sex-related differences in transporter regulation and GHB toxicokinetics. This study investigated the impact of exogenous estrogen and progesterone on GHB toxicokinetics and toxicodynamics, and evaluated the efficacy of AR-C155858 (an MCT1 inhibitor) to treat GHB overdose. Methods: Ovariectomized (OVX) females and castrated (CST) male Sprague Dawley rats were treated with estrogen and/or progesterone or a corresponding placebo for 21 days. Rats received intravenous GHB (1000 or 1500 mg/kg) or GHB + AR-C155858 (1500 mg/kg + 1 mg/kg), and plasma and urine samples were collected for 8 h post-dose. GHB concentrations were quantified by a validated LC/MS assay. Results: Female sex hormones significantly affected GHB toxicokinetics. Treatment with estrogen and progesterone (alone or in combination) reduced GHB exposure in OVX and CST rats through altered GHB clearance. Alterations in renal and metabolic clearance were dose-dependent. GHB exposure was significantly decreased with the co-administration of AR-C155858, as a result of increased GHB renal clearance. Conclusions: Female sex hormones influence GHB toxicokinetics, with combined estrogen/progesterone treatment producing the greatest reductions in systemic GHB exposure and toxicity. Monocarboxylate transporter inhibition with AR-C155858 significantly decreased GHB exposure and sedative effect, supporting its potential as a therapeutic strategy for GHB overdose across diverse populations.